These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28290753)

  • 1. Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome.
    Brownlee WJ; Chataway J
    Mult Scler; 2017 May; 23(6):876-877. PubMed ID: 28290753
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
    Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
    Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
    Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
    Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The First 90 Days: Temporary Effect of Alemtuzumab on CMV Immune Reconstitution.
    Abate D
    Transplantation; 2017 Jul; 101(7):1522. PubMed ID: 27918372
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.
    Helfrich M; Ison MG
    Transpl Infect Dis; 2015 Oct; 17(5):627-36. PubMed ID: 26228653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
    Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
    Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
    Nosari A; Tedeschi A; Ricci F; Montillo M
    Haematologica; 2008 Feb; 93(2):e30-1. PubMed ID: 18245646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
    Saadeh CE; Srkalovic G
    Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 18. [The clinician and cytomegalovirus infections].
    Almirante Gragera B; Pahissa Berga A
    Med Clin (Barc); 1990 Sep; 95(10):380-4. PubMed ID: 1964707
    [No Abstract]   [Full Text] [Related]  

  • 19. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
    Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
    Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus peritonitis after renal transplantation under induction therapy with alemtuzumab in a young woman previously treated with peritoneal dialysis.
    Meier M; Hiss M; Hafer C; Buth W; Radermacher J; Haller H; Schwarz A
    Nephrol Dial Transplant; 2005 Aug; 20(8):1771. PubMed ID: 15928098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.